| Availability: | |
|---|---|
| Quantity: | |
EIdd-2801
SINOBIO
2934999090
EIDD-2801/MK4482 (Monabiravir) Basic Information
Chinese Name: Monabiravir
English Name: Molnupiravir
CAS Number: 2492423-29-5
Molecular Formula: C₁₃H₁₉N₃O₇
Molecular Weight: 329.31 g/mol
Appearance: White or off-white powder
Purity: 99% (Research Grade/Pharmaceutical Grade)
Solubility: Soluble in DMSO (with ultrasonic assistance required), slightly soluble in water.
Storage Conditions: Store in a sealed, light-protected container at -20°C (avoid repeated freeze-thaw cycles).
Ridgeback announced that the US Food and Drug Administration (FDA) has approved the ind application for oral antiviral compound eidd-2801. The FDA's move allows Ridgeback to launch clinical trials of eidd-2801 in humans in the United States.
Eidd-2801 is an oral bioavailable form of highly effective ribonucleoside analogues, which can inhibit the replication of a variety of RNA viruses. The animal studies of two different coronaviruses showed that eidd-2801 could improve lung function, reduce weight loss and reduce the amount of virus in the lung.
EIDD-2801 is the isopropylester prodrug of N4-hydroxycytidine. With improved oral bioavailability in non human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5'-triphosphate form. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe.
| Product Name | EIDD-2801 |
| CAS | 2349386-89 |
| Appearance | White powder |
| MF | C13H19N3O |
| Molecular Weight | 329.31 |
| Purity | 99% min |
| Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder |
| Shelf Life | 24 Months |
* As a ribonucleoside analog, it incorporates into the viral RNA chain by mimicking the nucleotides required for RNA virus replication.
* Induces lethal mutations (error mutations) during viral RNA replication, thus preventing viral replication and transmission.
* Coronaviruses: SARS-CoV-2 (COVID-19), MERS-CoV, SARS-CoV.
* Influenza viruses: Seasonal influenza, pandemic influenza.
* Other viruses: Respiratory syncytial virus (RSV), Chikungunya virus, Ebola virus, etc.
* COVID-19 Treatment: Early clinical trials show it can shorten the course of the disease and reduce the risk of severe illness.
* Influenza Treatment: Effective against drug-resistant influenza virus strains, potentially becoming a novel anti-influenza drug.
* Virology Research: Used to explore the replication mechanisms of RNA viruses and develop antiviral drugs.
* Animal Model Experiments: To evaluate the effects of drugs on viral load, lung function, and body weight changes.
* As a precursor for the synthesis of antiviral drugs (such as EIDD-1931).
Packing: we can provide 1kg/bag, 25kg/drum. Different quantities have different packaging, according to your requirements
Shipping: by express DHL, FEDEX, TNT......or as your requirement
Payment: T/T,western union,moneygram or as your requirement
EIDD-2801/MK4482 (Monabiravir) Basic Information
Chinese Name: Monabiravir
English Name: Molnupiravir
CAS Number: 2492423-29-5
Molecular Formula: C₁₃H₁₉N₃O₇
Molecular Weight: 329.31 g/mol
Appearance: White or off-white powder
Purity: 99% (Research Grade/Pharmaceutical Grade)
Solubility: Soluble in DMSO (with ultrasonic assistance required), slightly soluble in water.
Storage Conditions: Store in a sealed, light-protected container at -20°C (avoid repeated freeze-thaw cycles).
Ridgeback announced that the US Food and Drug Administration (FDA) has approved the ind application for oral antiviral compound eidd-2801. The FDA's move allows Ridgeback to launch clinical trials of eidd-2801 in humans in the United States.
Eidd-2801 is an oral bioavailable form of highly effective ribonucleoside analogues, which can inhibit the replication of a variety of RNA viruses. The animal studies of two different coronaviruses showed that eidd-2801 could improve lung function, reduce weight loss and reduce the amount of virus in the lung.
EIDD-2801 is the isopropylester prodrug of N4-hydroxycytidine. With improved oral bioavailability in non human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5'-triphosphate form. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe.
| Product Name | EIDD-2801 |
| CAS | 2349386-89 |
| Appearance | White powder |
| MF | C13H19N3O |
| Molecular Weight | 329.31 |
| Purity | 99% min |
| Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder |
| Shelf Life | 24 Months |
* As a ribonucleoside analog, it incorporates into the viral RNA chain by mimicking the nucleotides required for RNA virus replication.
* Induces lethal mutations (error mutations) during viral RNA replication, thus preventing viral replication and transmission.
* Coronaviruses: SARS-CoV-2 (COVID-19), MERS-CoV, SARS-CoV.
* Influenza viruses: Seasonal influenza, pandemic influenza.
* Other viruses: Respiratory syncytial virus (RSV), Chikungunya virus, Ebola virus, etc.
* COVID-19 Treatment: Early clinical trials show it can shorten the course of the disease and reduce the risk of severe illness.
* Influenza Treatment: Effective against drug-resistant influenza virus strains, potentially becoming a novel anti-influenza drug.
* Virology Research: Used to explore the replication mechanisms of RNA viruses and develop antiviral drugs.
* Animal Model Experiments: To evaluate the effects of drugs on viral load, lung function, and body weight changes.
* As a precursor for the synthesis of antiviral drugs (such as EIDD-1931).
Packing: we can provide 1kg/bag, 25kg/drum. Different quantities have different packaging, according to your requirements
Shipping: by express DHL, FEDEX, TNT......or as your requirement
Payment: T/T,western union,moneygram or as your requirement